* . *
  • About
  • Advertise
  • Privacy & Policy
  • Contact
Saturday, September 6, 2025
Earth-News
  • Home
  • Business
  • Entertainment
  • General
  • Health
  • News

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • Science
  • Sports
  • Technology
    Coherent Joins LLNL’s STARFIRE Diode Technology Working Group to Advance Inertial Fusion Energy – GlobeNewswire

    Coherent Partners with LLNL’s STARFIRE Team to Drive Breakthroughs in Inertial Fusion Energy

    Gene Associated With Deadly Heart Disease in Golden Retrievers Identified – Technology Networks

    Breakthrough Discovery Uncovers Gene Behind Deadly Heart Disease in Golden Retrievers

    Monkey Island LNG Picks ConocoPhillips’ Liquefaction Technology – Hart Energy

    Monkey Island LNG Selects ConocoPhillips’ Advanced Liquefaction Technology for Next-Gen Energy Solutions

    Credo Technology Group Holding Ltd. (CRDO) Surpasses Q1 Earnings and Revenue Estimates – Yahoo Finance

    Credo Technology Group Surpasses Q1 Earnings and Revenue Expectations

    The Economist is hiring a science and technology correspondent – The Economist

    Exciting Opportunity: Become Our Next Science and Technology Correspondent!

    Blockchain lender Figure Technology seeks to raise up to $526M in IPO (FIGR:Pending) – Seeking Alpha

    Blockchain Lender Figure Technology Sets Sights on $526M in Thrilling IPO Launch

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
No Result
View All Result
  • Home
  • Business
  • Entertainment
  • General
  • Health
  • News

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • Science
  • Sports
  • Technology
    Coherent Joins LLNL’s STARFIRE Diode Technology Working Group to Advance Inertial Fusion Energy – GlobeNewswire

    Coherent Partners with LLNL’s STARFIRE Team to Drive Breakthroughs in Inertial Fusion Energy

    Gene Associated With Deadly Heart Disease in Golden Retrievers Identified – Technology Networks

    Breakthrough Discovery Uncovers Gene Behind Deadly Heart Disease in Golden Retrievers

    Monkey Island LNG Picks ConocoPhillips’ Liquefaction Technology – Hart Energy

    Monkey Island LNG Selects ConocoPhillips’ Advanced Liquefaction Technology for Next-Gen Energy Solutions

    Credo Technology Group Holding Ltd. (CRDO) Surpasses Q1 Earnings and Revenue Estimates – Yahoo Finance

    Credo Technology Group Surpasses Q1 Earnings and Revenue Expectations

    The Economist is hiring a science and technology correspondent – The Economist

    Exciting Opportunity: Become Our Next Science and Technology Correspondent!

    Blockchain lender Figure Technology seeks to raise up to $526M in IPO (FIGR:Pending) – Seeking Alpha

    Blockchain Lender Figure Technology Sets Sights on $526M in Thrilling IPO Launch

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
No Result
View All Result
Earth-News
No Result
View All Result
Home Health

New Targeted Drug OK’d for Acute Myeloid Leukemia

July 24, 2023
in Health
New Targeted Drug OK’d for Acute Myeloid Leukemia
Share on FacebookShare on Twitter

The FDA approved quizartinib (Vanflyta) for FLT3 internal tandem duplication (ITD)-positive acute myeloid leukemia (AML), the agency announced on Thursday.

Quizartinib is indicated for newly diagnosed patients in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy for patients who do not undergo allogeneic hematopoietic stem cell transplantation (HSCT). The FDA noted that quizartinib is not indicated as maintenance monotherapy following allogeneic HSCT, where its efficacy has not been assessed.

Support for approval was based on results from QuANTUM-First, a phase III study of over 500 AML patients with FLT3-ITD positive disease undergoing standard induction and consolidation therapy. Median overall survival doubled for patients randomized to the FLT3 inhibitor rather than placebo from induction through maintenance (31.9 vs 15.1 months, respectively; HR 0.78, 95% CI 0.62-0.98, P=0.032).

And median duration of remission, a secondary outcome, was significantly longer in the quizartinib arm (38.6 vs 12.4 months with placebo).

With the approval, quizartinib becomes the “first and only” FLT3 inhibitor to receive approval specifically for FLT3-ITD positive AML across these three phases of treatment, according to drug developer Daiichi Sankyo.

“The approval of Vanflyta represents a significant advancement for the treatment of patients with newly diagnosed FLT3-ITD-positive AML, which is one of the most aggressive and difficult-to-treat subtypes,” said trial investigator Harry Erba, MD, PhD, of the Duke Cancer Institute in Durham, North Carolina, in a press release from the drugmaker.

“In the QuANTUM-First trial, Vanflyta added to standard chemotherapy and continued as maintenance resulted in longer remission and prolonged overall survival and it will be a much-needed new treatment option that has potential to change the way FLT3-ITD positive AML is treated,” he added.

The companion diagnostic LeukoStrat CDx FLT3 Mutation Assay has also been approved to assess patients’ eligibility for quizartinib.

A boxed warning in the labeling for quizartinib notes the risk for QT prolongation, torsades de pointes, and cardiac arrest, and the drug will be available under a risk evaluation and mitigation strategy (REMS) program due to these risks.

The most common grade 3/4 adverse events (AEs) in QuANTUM-First included febrile neutropenia, hypokalemia, and pneumonia in both groups and neutropenia in the quizartinib group. Serious AEs occurring in at least 5% of patients in the quizartinib arm included febrile neutropenia (11%).

Fatal AEs occurred in 10% of quizartinib-treated patients and included sepsis (5%), fungal infections (0.8%), brain edema (0.8%), and one case each of febrile neutropenia, pneumonia, cerebral infarction, acute respiratory distress syndrome, pulmonary embolism, ventricular dysfunction, and cardiac arrest.

Permanent discontinuation of therapy due to AEs occurred in 20% of patients, while dose interruptions occurred in a third.

author['full_name']

Mike Bassett is a staff writer focusing on oncology and hematology. He is based in Massachusetts.

>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : MedPageToday – https://www.medpagetoday.com/hematologyoncology/leukemia/105592

Tags: AcutehealthTargeted
Previous Post

USPSTF Decision on Adult Suicide Screening Falls Flat

Next Post

Long COVID Persists as a Mass Disabling Event

Ecology issues $738K penalty against downtown Walla Walla Chevron owner – Union-Bulletin

Ecology issues $738K penalty against downtown Walla Walla Chevron owner – Union-Bulletin

September 6, 2025
What the science says about acetaminophen, pregnant mothers and autism – NBC News

What the science says about acetaminophen, pregnant mothers and autism – NBC News

September 6, 2025
RFK Jr accused of ‘reckless disregard for science and the truth’ in Senate hearing – The Guardian

RFK Jr. Faces Fierce Backlash for ‘Reckless Disregard for Science and Truth’ in Heated Senate Hearing

September 6, 2025
Start The Go-Go Years Today: Ignite Your Early Retirement Lifestyle – Forbes

Start The Go-Go Years Today: Ignite Your Early Retirement Lifestyle – Forbes

September 6, 2025
When Sports Teach More Than Skills – American Enterprise Institute

When Sports Teach More Than Skills – American Enterprise Institute

September 6, 2025
Abby Dow and England near record territory as Australia search for upset – The Guardian

Abby Dow and England Close in on Record as Australia Hunts for an Upset

September 6, 2025
America is getting the economy we voted for – Noah Smith | Substack

America Is Finally Experiencing the Economy We Created

September 6, 2025
Pendulum Announce Homecoming 2026 Australian Tour – yahoo.com

Pendulum Announces Thrilling Homecoming Tour Across Australia in 2026

September 6, 2025
HHS responds to report about autism and acetaminophen : Shots – Health News – NPR

HHS Addresses New Findings on Autism and Acetaminophen Use

September 6, 2025
September 2, 2025: Trump administration news – CNN

September 2, 2025: Trump administration news – CNN

September 6, 2025

Categories

Archives

September 2025
MTWTFSS
1234567
891011121314
15161718192021
22232425262728
2930 
« Aug    
Earth-News.info

The Earth News is an independent English-language daily published Website from all around the World News

Browse by Category

  • Business (20,132)
  • Ecology (810)
  • Economy (828)
  • Entertainment (21,705)
  • General (16,889)
  • Health (9,869)
  • Lifestyle (841)
  • News (22,149)
  • People (830)
  • Politics (835)
  • Science (16,039)
  • Sports (21,327)
  • Technology (15,808)
  • World (809)

Recent News

Ecology issues $738K penalty against downtown Walla Walla Chevron owner – Union-Bulletin

Ecology issues $738K penalty against downtown Walla Walla Chevron owner – Union-Bulletin

September 6, 2025
What the science says about acetaminophen, pregnant mothers and autism – NBC News

What the science says about acetaminophen, pregnant mothers and autism – NBC News

September 6, 2025
  • About
  • Advertise
  • Privacy & Policy
  • Contact

© 2023 earth-news.info

No Result
View All Result

© 2023 earth-news.info

No Result
View All Result

© 2023 earth-news.info

Go to mobile version